A 5-Question Quiz on Multiple Myeloma

Harnessing PIPAC to Improve Outcomes in Peritoneal Carcinomatosis

Data from the phase 1/2 WU-KONG1 study support the accelerated approval of sunvozertinib in this population.

Benjamin Golas, MD, discusses how the use of PIPAC may work in conjunction with systemic chemotherapy for those with peritoneal carcinomatosis.

Benjamin J. Golas, MD

June 30th 2025

Comparing CAR T Safety, Efficacy in Relapsed/Refractory Multiple Myeloma

Benjamin Golas, MD, discusses how the use of PIPAC may work in conjunction with systemic chemotherapy for those with peritoneal carcinomatosis.

$The expert panel discussed the efficacy observed with cilta-cel in patients with relapsed/refractory multiple myeloma.$

Practice-Changing Lung Cancer Data From the 2025 ASCO Annual Meeting

The expert panel discussed the efficacy observed with cilta-cel in patients with relapsed/refractory multiple myeloma.

Stephen Liu, MD, and Joshua Sabari, MD, discuss the most intriguing non–small cell lung cancer and small cell lung cancer breakthroughs from the meeting.

Stephen V. Liu, MD;Joshua K. Sabari, MD

June 23rd 2025

Linvoseltamab Earns FDA Accelerated Approval for R/R Multiple Myeloma

Stephen Liu, MD; and Joshua Sabari, MD, discuss the most intriguing non–small cell lung cancer and small cell lung cancer breakthroughs from the meeting.

Data supporting the FDA decision came from the phase 1/2 LINKER-MM1 (NCT03761108) trial.

SonoClear System Earns Breakthrough Designation for Intracranial Procedures

Data supporting the FDA decision came from the phase 1/2 LINKER-MM1 trial.

The system showed enhanced diagnostic accuracy of intraoperative imaging, potentially improving the extent of resection while reducing residual disease.

Sunvozertinib Earns FDA Accelerated Approval in EGFR Exon 20+ NSCLC

The system showed enhanced diagnostic accuracy of intraoperative imaging, potentially improving the extent of resection while reducing residual disease.

Related Content

Russ Conroy

Harnessing PIPAC to Improve Outcomes in Peritoneal Carcinomatosis

Data from the phase 1/2 WU-KONG1 study support the accelerated approval of sunvozertinib in this population.

Benjamin J. Golas, MD

June 30th 2025

Comparing CAR T Safety, Efficacy in Relapsed/Refractory Multiple Myeloma

Benjamin Golas, MD, discusses how the use of PIPAC may work in conjunction with systemic chemotherapy for those with peritoneal carcinomatosis.

$The expert panel discussed the efficacy observed with cilta-cel in patients with relapsed/refractory multiple myeloma.$

Practice-Changing Lung Cancer Data From the 2025 ASCO Annual Meeting

The expert panel discussed the efficacy observed with cilta-cel in patients with relapsed/refractory multiple myeloma.

Stephen V. Liu, MD;Joshua K. Sabari, MD

June 23rd 2025

Linvoseltamab Earns FDA Accelerated Approval for R/R Multiple Myeloma

Stephen Liu, MD; and Joshua Sabari, MD, discuss the most intriguing non–small cell lung cancer and small cell lung cancer breakthroughs from the meeting.

SonoClear System Earns Breakthrough Designation for Intracranial Procedures

Data supporting the FDA decision came from the phase 1/2 LINKER-MM1 trial.